Kairos Pharma Ltd. (NYSE American: KAPA) announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO(R) (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance and is currently being evaluated in Phase 1 and Phase 2 clinical trials. The company previously reported interim Phase 2 data showing median progression-free survival of more than 13 months in prostate cancer patients, while XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.
The collaboration will evaluate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer. For more details, the full press release is available at https://ibn.fm/emSc4.
Kairos Pharma, based in Los Angeles, is focused on oncology therapeutics, using structural biology to overcome drug resistance and immune suppression. Its lead candidate, ENV-105, targets CD105, a key driver of resistance and relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the FDA or any foreign regulator.
This collaboration is significant because it combines a novel mechanism to overcome treatment resistance with an established radiopharmaceutical, potentially improving outcomes for patients with limited options. The partnership leverages Bayer’s expertise in oncology and Kairos’s innovative approach to targeting CD105. Further updates are available in the company’s newsroom at https://ibn.fm/KAPA.
